Gamma Therapeutics, Inc., an early stage OHSU biotech startup company, was selected by the National Science Foundation (NSF) as one of 50 companies to exhibit and showcase their technology in the world’s largest biotech conference. Held June 6-9 in San Francisco, the Biotechnology Innovation Organization (BIO) International Convention attracted nearly 15,000 biotech leaders from over 65 countries. The event covered the wide spectrum of life science innovations and application areas, including drug discovery, bio manufacturing, genomics, biofuels, nanotechnology, and cell therapy. Gamma Therapeutics Founder and Chief Scientific Officer, David Farrell, Ph.D., F.A.H.A., represented the company as one of the few Oregon-based companies at the BIO Convention.
BIO recognized Gamma Therapeutics for the company’s recent NSF STTR Phase I award. Gamma’s products, which are based on OHSU technologies, are in the cardiovascular disease risk assessment, surgical therapy and combat casualty care spaces. The NSF STTR grant was awarded to develop a physiological initiator protein to enable rapid blood clotting to treat bleeding after a traumatic injury. Other products in Gamma Therapeutics’ product line include its flagship product, GammaCoeur ™, a cardiovascular disease risk diagnostic assay; GammaSeal™, a patented, high-strength post-surgical incision sealant; and Gammarin™, a patented non-immunogenic blood anti-coagulant.
Farrell hopes to bring more recognition and partners to the State of Oregon. “This was a great opportunity to bring international attention to the high quality of new inventions and discoveries coming out of Oregon, which could attract strategic industry partners and venture investment to Oregon.”